Abstract
Since 1976, panretinal photocoagulation (PRP) has been the preconized treatment for proliferative diabetic retinopathy (PDR). However, the procedure decreases the risk of severe vision loss by only 50%, and is associated with substantial burden and retinal damage. Therefore, alternative therapy modalities, such as association of intravitreal injection of anti-VEGF agents and pattern scan …